Shuttle Pharma Issued U.S. Patent For Selective Histone Deacetylase Inhibitors For Treatment Of Human Disease
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharma has been granted a U.S. patent for its selective histone deacetylase inhibitors, which are used in the treatment of human diseases. This development could enhance the company's intellectual property portfolio and potentially lead to new therapeutic applications.
September 05, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharma has received a U.S. patent for its selective histone deacetylase inhibitors, which could strengthen its market position and open up new therapeutic avenues.
The granting of a U.S. patent is a significant milestone for Shuttle Pharma, as it enhances the company's intellectual property and could lead to new product developments. This is likely to positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100